PHARMASGP HOLDING SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.2 EUR | -4.31% |
|
-2.63% | -1.33% |
| 05-28 | PharmaSGP Holding SE Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-29 | PharmaSGP Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 312 | 296.4 | 319.2 | 270 | 266.2 | - | - |
| Enterprise Value (EV) 1 | 304.4 | 275.8 | 368.1 | 303.2 | 278.4 | 261.9 | 223.3 |
| P/E ratio | 29.2 x | 27.8 x | 26.6 x | 16.4 x | 13.4 x | 12.2 x | 10 x |
| Yield | - | 1.82% | 1.84% | 6.04% | 2.34% | 3.09% | 3.4% |
| Capitalization / Revenue | 4.93 x | 4.54 x | 3.72 x | 2.67 x | 2.41 x | 2.24 x | 2.08 x |
| EV / Revenue | 4.81 x | 4.22 x | 4.29 x | 3 x | 2.52 x | 2.21 x | 1.75 x |
| EV / EBITDA | 17.9 x | 14.2 x | 13 x | 8.89 x | 7.54 x | 6.49 x | 5.11 x |
| EV / FCF | 20.2 x | 22.7 x | 15.4 x | - | 9.28 x | 8.66 x | - |
| FCF Yield | 4.94% | 4.4% | 6.5% | - | 10.8% | 11.6% | - |
| Price to Book | 27.1 x | 13.4 x | 10.3 x | 6.79 x | 4.95 x | 4.31 x | 4.1 x |
| Nbr of stocks (in thousands) | 12,000 | 12,000 | 12,000 | 12,000 | 11,990 | - | - |
| Reference price 2 | 26.00 | 24.70 | 26.60 | 22.50 | 22.20 | 22.20 | 22.20 |
| Announcement Date | 4/29/21 | 4/28/22 | 4/28/23 | 4/29/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 63.25 | 65.34 | 85.82 | 101.1 | 110.4 | 118.8 | 127.8 |
| EBITDA 1 | 17 | 19.43 | 28.23 | 34.09 | 36.9 | 40.35 | 43.7 |
| EBIT 1 | 16.52 | 15.9 | 19 | 24.7 | 35.4 | 34.95 | 41.9 |
| Operating Margin | 26.12% | 24.33% | 22.14% | 24.43% | 32.05% | 29.43% | 32.8% |
| Earnings before Tax (EBT) 1 | 14.15 | 14.21 | 15.8 | 21.89 | 24 | 27 | -4 |
| Net income 1 | 10.64 | 10.69 | 11.95 | 16.4 | 20 | 21.8 | 24.8 |
| Net margin | 16.82% | 16.36% | 13.93% | 16.22% | 18.11% | 18.36% | 19.41% |
| EPS 2 | 0.8900 | 0.8900 | 1.000 | 1.370 | 1.660 | 1.820 | 2.220 |
| Free Cash Flow 1 | 15.04 | 12.15 | 23.93 | - | 30 | 30.25 | - |
| FCF margin | 23.78% | 18.59% | 27.88% | - | 27.16% | 25.47% | - |
| FCF Conversion (EBITDA) | 88.46% | 62.51% | 84.76% | - | 81.3% | 74.97% | - |
| FCF Conversion (Net income) | 141.33% | 113.62% | 200.15% | - | 150% | 138.76% | - |
| Dividend per Share 2 | - | 0.4500 | 0.4900 | 1.360 | 0.5200 | 0.6850 | 0.7550 |
| Announcement Date | 4/29/21 | 4/28/22 | 4/28/23 | 4/29/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 19.18 | 20.57 | 21.43 | 41.99 | 21.95 | 21.88 | 24.01 | 25.7 | 49.71 | 25.97 | 25.42 | 27.8 | 58 | 27.2 | 26.6 |
| EBITDA 1 | - | 6.192 | 4.997 | 7.079 | 12.08 | 8.3 | 7.853 | 7.011 | 8.417 | 15.43 | 9.289 | 9.371 | 9.1 | 17.9 | 9.5 | 9.5 |
| EBIT 1 | - | 4.575 | 2.731 | 4.778 | 7.509 | 5.981 | 5.489 | 4.7 | 6.06 | 10.76 | 6.948 | 6.992 | 8.7 | 17.4 | 9.2 | 8.9 |
| Operating Margin | - | 23.85% | 13.28% | 22.3% | 17.88% | 27.25% | 25.09% | 19.57% | 23.58% | 21.65% | 26.76% | 27.5% | 31.29% | 30% | 33.82% | 33.46% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 7.106 | 2.393 | 1.681 | 2.984 | 4.665 | 3.946 | 3.343 | 2.845 | 4.017 | 6.862 | 4.786 | 4.749 | 4.9 | 9.5 | 5.3 | 5.2 |
| Net margin | - | 12.48% | 8.17% | 13.93% | 11.11% | 17.98% | 15.28% | 11.85% | 15.63% | 13.8% | 18.43% | 18.68% | 17.63% | 16.38% | 19.49% | 19.55% |
| EPS 2 | 0.5900 | 0.2000 | - | 0.2500 | 0.3900 | 0.3300 | 0.2800 | 0.2400 | 0.3300 | 0.5700 | 0.4000 | 0.4000 | 0.4100 | 0.7900 | 0.4400 | 0.4400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/30/20 | 4/28/22 | 5/31/22 | 9/28/22 | 9/28/22 | 11/30/22 | 4/28/23 | 5/26/23 | 9/30/23 | 9/30/23 | 11/28/23 | 4/29/24 | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 48.9 | 33.2 | 12.2 | - | - |
| Net Cash position 1 | 7.62 | 20.6 | - | - | - | 4.3 | 42.9 |
| Leverage (Debt/EBITDA) | - | - | 1.732 x | 0.9743 x | 0.3306 x | - | - |
| Free Cash Flow 1 | 15 | 12.1 | 23.9 | - | 30 | 30.3 | - |
| ROE (net income / shareholders' equity) | - | 63.4% | 44.9% | 46.3% | 50.2% | 43.9% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.9600 | 1.850 | 2.590 | 3.310 | 4.490 | 5.150 | 5.410 |
| Cash Flow per Share | 1.290 | - | - | - | - | - | - |
| Capex 1 | 0.42 | 0.09 | 0.79 | - | 0.5 | 0.75 | 0.5 |
| Capex / Sales | 0.66% | 0.14% | 0.92% | - | 0.45% | 0.63% | 0.39% |
| Announcement Date | 4/29/21 | 4/28/22 | 4/28/23 | 4/29/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
22.2
EUR
Average target price
38.75
EUR
Spread / Average Target
+74.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.33% | 298M | |
| +56.86% | 815B | |
| +43.90% | 641B | |
| -6.57% | 352B | |
| +17.32% | 314B | |
| +9.94% | 303B | |
| +16.08% | 242B | |
| +2.29% | 224B | |
| +13.96% | 218B | |
| +7.98% | 168B |
- Stock Market
- Equities
- PSG Stock
- Financials PharmaSGP Holding SE
